Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2009

View Archived Issues

Novel tools for post-transplant tacrolimus dose optimization reported

Banyu describes 4-sulfonylpiperidine derivatives for the treatment of diabetes

Kitasato Institute and Kyowa Hakko Kirin claim novel KB-3346-5 substances as antiinfective agents

Improved early virologic response rates seen with GI-5005 in phase II HCV study

Preclinical data on phase I antiangiogenic mAb, PF-03446962, presented

AEZS-126, a new orally bioavailable PI3K inhibitor shows preclinical antitumor activity

Intravitreal viral delivery of VEGF antagonist developed as therapy for ocular neovascularization

Intarcia completes enrollment in phase Ib clinical study of ITCA-650 in type 2 diabetes

Novel multitargeted kinase inhibitor displays potent antitumor activity in preclinical cancer models

Choongwae patents GSK-3beta inhibitors for the treatment of Alzheimer's disease

Novel PI3K inhibitors for cancer treatment jointly patented by Genentech and Roche

Antisense begins pivotal phase III trabedersen trial in aggressive brain tumors

Avila Therapeutics' novel agent AVL-181 silences HCV protease activity

Peregrine presents preliminary phase II bavituximab data in breast cancer

Pharmasset and Roche dose first patient in phase IIb clinical trial of HCV drug R-7128

CHMP recommends approval of pediatric formulation of Tracleer in PAH

Clinical study shows anti-HCV efficacy of NIM-811 with peginterferon

Janssen receives Japanese approval to market Risperdal Consta for schizophrenia

European Commission grants Wyeth marketing authorization for Conbriza

Novel Aurora kinase inhibitors claimed by Bayer for cancer treatment

FDA accepts for review Theravance's complete response for telavancin in cSSSI

FDA grants orphan drug designation to Pharming's Prodarsan for Cockayne syndrome

Phase III Nexavar trial in advanced melanoma does not meet primary endpoint

Phase II GSK-1838262 results reported for pain in diabetic peripheral neuropathy

Sepracor reports preliminary phase III Omnaris results in allergic rhinitis

Once-daily antiepileptic Zebinix approved in the European Union

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...